[The prevention of deep venous thrombosis in patients undergoing an internal arteriovenous fistula intervention].
Twenty patients, submitted to internal arteriovenous fistula procedure, were randomly assigned to one of the following treatments: defibrotide 400 mg b.i.d. IM (starting the day before surgery and continuing for the following 7 days); calcium heparin 5,000 IU t.i.d. SC (since the day of surgery and for the following 7 days). No deep venous thrombosis or thrombosis of the fistula were noticed during both treatments and no side effects were observed. In the defibrotide group, ELT showed a significant decrease (-40%) attesting an improvement of fibrinolysis without a plasminogen abatement. These findings indicate that defibrotide represent an effective alternative to calcium heparin for antithrombotic prophylaxis of A-V fistula in uremic patients.
Picone
F P
FP
Istituto di Patologia Chirurgica, Università degli Studi di Palermo.
Lombardo
A
A
Rapisarda
L M
LM
Giambruno
M
M
Gerosa
C
C
Nazzari
M
M
D001166:Arteriovenous Shunt, Surgical; D004361:Drug Tolerance; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000517:prevention & control*; D014511:Uremia / Q000097:blood / Q000601:surgery
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C006871:calcium heparin; C036901:defibrotide; D006493:Heparin